Fortuna Mining Corp. Common Shares vs Moderna, Inc. — how do they compare? Fortuna Mining Corp. Common Shares trades at $10.76 (market cap $3.01B), while Moderna, Inc. trades at $196.72 (market cap $78.44B). The key difference: Moderna, Inc. is far larger — about 26.1× Fortuna Mining Corp. Common Shares's market cap, and Moderna, Inc. is trading nearer its 52-week high, Fortuna Mining Corp. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fortuna Mining Corp. Common Shares for 0 Days and Moderna, Inc. for 59 Days on average.
| FSM | MRNA | |
|---|---|---|
Market Cap | $3.01B | $78.44B |
Volume | 10,925,733 | 14,597,511 |
Sector | Basic Materials | Health |
52-Week High | $13.66 | $203.46 |
52-Week Low | $7.84 | $22.36 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $2.63B | $74.59B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $197.00, up 5.09% today, with a bullish technical signal supported by moving averages. Recent inclusion in the Nasdaq-100 index has driven positive momentum, though the stock faces valuation concerns after a 500% rally in 2026. Financially, revenue has declined from $18.9B in 2022 to $1.92B in 2025, with net losses widening to -$2.82B. Earnings have consistently beaten expectations, but profitability metrics remain negative.
Outlook: Near-term upside may be capped by high valuations and profit-taking pressure, but long-term growth potential exists in the oncology pipeline. Key risks include sustained revenue declines, competitive threats, and reliance on pipeline success. Analysts are mixed, with a consensus price target of $115.70 suggesting caution despite bullish technicals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Fortuna Mining is a Canadian precious-metals mining company with operations in Latin America and West Africa. It produces gold and silver and conducts exploration activities in several countries.
Read more on FSM →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →